Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
domingo, octubre 25
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Bolt Biotherapeutics Inc
BOLT
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$6.27
2.08
49.64%
Últ. Act.: Oct 23, 7:59 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Fusiones y adquisiciones:
Prana Therapies, Inc was acquired by Bolt Biotherapeutics (BOLT) on Friday, October 23, 2026
Bolt Biotherapeutics Financials
Bolt Biotherapeutics (BOLT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent. This is a 2.47 percent decrease over losses of $(4.46) per share
Benzinga Newsdesk
PRO
Bolt Biotherapeutics Q1 EPS $(4.31) Misses $(2.85) Estimate, Sales $26.000K Miss $1.500M Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.31) per share which missed the analyst consensus estimate of $(2.85) by 51.23 percent. This is a 25.69 percent increase over losses of $(5.80) per share
Benzinga Newsdesk
PRO
Bolt Biotherapeutics Q4 EPS $(3.84) Beats $(4.30) Estimate, Sales $2.500M Beat $666.667K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(3.84) per share which beat the analyst consensus estimate of $(4.30) by 10.7 percent. This is a 49.47 percent increase over losses of $(7.60) per share
Benzinga Newsdesk
PRO
Bolt Biotherapeutics Q3 EPS $(3.72) Beats $(5.53) Estimate, Sales $2.169M Beat $725.000K Estimate
Benzinga Newsdesk
PRO
Bolt Biotherapeutics Q2 EPS $(4.46) Beats $(6.27) Estimate, Sales $1.80M Beat $819.75K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.46) per share which beat the analyst consensus estimate of $(6.27) by 28.83 percent. This is a 60.18 percent increase over losses of $(11.20) per share
Benzinga Newsdesk
PRO
Bolt Biotherapeutics Q1 EPS $(0.29) Beats $(0.36) Estimate, Sales $1.22M Beat $767.50K Estimate
Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.36) by 19.44 percent. This is a 3.57 percent decrease over losses of $(0.28) per share
Benzinga Newsdesk
